TY - JOUR
T1 - Viral and host factors associated with SARSCoV-2 disease severity in Georgia, USA
AU - Carmola, Ludy R.
AU - Roebling, Allison Dorothy
AU - Khosravi, Dara
AU - Langsjoen, Rose M.
AU - Bombin, Andrei
AU - Bixler, Bri
AU - Reid, Alex
AU - Chen, Cara
AU - Wang, Ethan
AU - Lu, Yang
AU - Zheng, Ziduo
AU - Zhang, Rebecca
AU - Nguyen, Phuong Vi
AU - Arthur, Robert A.
AU - Fitts, Eric
AU - Gulick, Dalia Arafat
AU - Higginbotham, Dustin
AU - Taz, Azmain
AU - Ahmed, Alaa
AU - Crumpler, John Hunter
AU - Kraft, Colleen
AU - Lam, Wilbur A.
AU - Babiker, Ahmed
AU - Waggoner, Jesse J.
AU - Openo, Kyle P.
AU - Johnson, Laura M.
AU - Westbrook, Adrianna
AU - Piantadosi, Anne
N1 - Publisher Copyright:
© 2025 Carmola et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/4
Y1 - 2025/4
N2 - While SARS-CoV-2 vaccines have shown strong efficacy, the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19, especially in locations with suboptimal vaccination uptake. We investigated viral and host factors, including vaccination status, that were associated with SARSCoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within the prior 3-9 months was associated with decreased odds of moderate disease, severe disease, and death. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.
AB - While SARS-CoV-2 vaccines have shown strong efficacy, the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19, especially in locations with suboptimal vaccination uptake. We investigated viral and host factors, including vaccination status, that were associated with SARSCoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within the prior 3-9 months was associated with decreased odds of moderate disease, severe disease, and death. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.
UR - https://www.scopus.com/pages/publications/105001652877
UR - https://www.scopus.com/pages/publications/105001652877#tab=citedBy
U2 - 10.1371/journal.pone.0317972
DO - 10.1371/journal.pone.0317972
M3 - Article
C2 - 40168303
AN - SCOPUS:105001652877
SN - 1932-6203
VL - 20
JO - PloS one
JF - PloS one
IS - 4 April
M1 - e0317972
ER -